Abstract

CASE STUDY OF GLIMEPIRIDE IN PHARMACEUTICAL MARKET

Vishal Agrahari*, Devashish Jena and Pravesh Kumar Gupta

.

Abstract

Glimepiride is a third-generation sulfonylurea oral hypoglycemic drug with extensive use in type 2 diabetes mellitus (T2DM) management. Glimepiride works mainly by inducing insulin release from pancreatic β-cells and increasing peripheral insulin sensitivity. Glimepiride has a short onset of action and long duration, enabling once-daily dosing. Relative to older sulfonylureas, it is less likely to cause hypoglycemia and has a better safety profile, and thus is widely used in combination with other antidiabetic drugs like metformin or insulin. Glimepiride is pharmacokinetically well-absorbed, hepatically metabolized (CYP2C9), and excreted in urine and feces. Clinical trials have demonstrated its effectiveness in glucose control, with potential added benefits on cardiovascular parameters.

Keywords: Glimepiride, Drug Profile, Pharmaceutical Marketing, Drug Lifecycle Management, Generic Drugs, Patent Expiry, Marketing Strategy, Pharmaceutical Industry.